GlassScriptPhysician profile
Eugene K Herman
NPI 1801876164
$3,977.13
in general payments reported to CMS, 2019-2025
29 companies · $64.85 in 2025
The $64.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $267 · 2021: $277 · 2022: $1,079 · 2023: $977 · 2024: $24.68 · 2025: $64.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $907.09 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $446.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $428.04 | 2019-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $345.07 | 2022-2023 | |
| Pfizer INC. | $244.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $213.07 | 2019-2023 | |
| Lilly USA, LLC | $148.65 | 2019-2023 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $144.13 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $139.28 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.27 | 2022-2023 | Jardiance, Ofev |
| Abbott Laboratories | $110.17 | 2022-2025 | Freestyle Libre 3 |
| Ablative Solutions, INC. | $109.09 | 2020 | |
| Amgen INC. | $108.67 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $96.53 | 2019-2023 | Unithroid |
| Glaxosmithkline, LLC. | $62.31 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55.75 | 2019-2023 | |
| Shield Therapeutics INC | $44.33 | 2022-2023 | Accrufer |
| Exact Sciences Corporation | $42.70 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $28.94 | 2019 | |
| Daiichi Sankyo INC. | $28.29 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.28 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $17.62 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.77 | 2022 | |
| Promius Pharma LLC | $15.46 | 2019 | |
| Esperion Therapeutics, INC. | $15.13 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $14.49 | 2019 | |
| Dexcom, INC. | $14.45 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $13.33 | 2023 | Contrave |
| Nalpropion Pharmaceuticals LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.